SNES
SenesTechBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Primary sources support a modestly better commercial profile: 2025 revenue grew to $2.2 million, e-commerce revenue increased, and management described gross-margin improvement alongside a narrower adjusted EBITDA loss [#8-K-2026-03-12].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Amazon direct-management execution is still unproven after an estimated $200,000 2025 revenue hit during the transition [#8-K-2026-03-12].
Momentum
85
Value
59
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.55 · Bull $2.10 · Bear $0.75
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum85 · Δ7d -
Value59 · Δ7d -0.1
Sentiment37 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.2
Sentiment
37
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 84.6 / Value 58.5 / Sentiment 37.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$8.96M
Beta
0.22
Shares Out
5.22M
P/E (TTM) · Derived
-0.2
P/S (TTM)
5.08
P/FCF (TTM) · Derived
-0.70
Rev YoY
+43.2%
EPS YoY
+86.6%
Gross Margin
+63.5%
Op Margin
-255.6%
Net Debt
-$1.04M
Current Ratio
15.75
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology